|
|
Volumn 278, Issue 5340, 1997, Pages 1036-1039
|
|
From bench top to bedside
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
COMPLEMENTARY DNA;
FARNESYL TRANS TRANSFERASE;
PROTEIN TYROSINE KINASE INHIBITOR;
ANTINEOPLASTIC ACTIVITY;
CANCER;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER RESEARCH;
HUMAN;
NOTE;
ONCOGENE;
PRIORITY JOURNAL;
TUMOR SUPPRESSOR GENE;
ALKYL AND ARYL TRANSFERASES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
BINDING SITES;
CLINICAL TRIALS;
CYCLIN-DEPENDENT KINASES;
DRUG DESIGN;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
GENE THERAPY;
GENES, P53;
GENES, TUMOR SUPPRESSOR;
HUMANS;
NEOPLASMS;
ONCOGENES;
PROTEIN-TYROSINE KINASES;
PROTO-ONCOGENE PROTEINS C-BCL-2;
RAS PROTEINS;
RECEPTOR, ERBB-2;
RECEPTORS, GROWTH FACTOR;
|
|
EID: 0030667205
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.278.5340.1036 Document Type: Note |
|
Times cited : (89)
|
|
References (0)
|